6-(4-aminophenyl)-5-(N-benzyl-N-methylaminomethyl)-1-(2,6-difluorobenzyl)-3-phenylthieno[2,3-d]pyrimidine-2,4(1H,3H)-dione | 174072-63-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩并嘧啶酮衍生物
• 英文名称: 6-(4-aminophenyl)-5-(N-benzyl-N-methylaminomethyl)-1-(2,6-difluorobenzyl)-3-phenylthieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
• 英文别名: 6-(4-aminophenyl)-2,4-(1H,3H)-dioxo-1-(2,6-difluorobenzyl)-5-(N-methyl-N-benzylaminomethyl)-3-phenylthieno[2,3-d]pyrimidine；1-(2,6-difluorobenzyl)-6-(4-aminophenyl)-5-((benzyl(methyl)amino)methyl)-3-phenylthieno[2,3-d]pyrimidine-2,4(1H,3H)-dione；6-(4-aminophenyl)-5-[[benzyl(methyl)amino]methyl]-1-[(2,6-difluorophenyl)methyl]-3-phenylthieno[2,3-d]pyrimidine-2,4-dione
• CAS: 174072-63-0
• 化学式: C₃₄H₂₈F₂N₄O₂S
• 分子量: 594.685
• InChiKey: FOXVBEONEKPPOA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.4
• 重原子数：
  43
• 可旋转键数：
  8
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  98.1
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  6-(4-aminophenyl)-5-(N-benzyl-N-methylaminomethyl)-1-(2,6-difluorobenzyl)-3-phenylthieno[2,3-d]pyrimidine-2,4(1H,3H)-dione 以71的产率得到舒夫戈利
  参考文献：
  名称：

  J. Med. Chem. 2003, 46, 113-124

  摘要：

  DOI：
• 作为产物：
  描述：

  5-(N-benzyl-N-methylaminomethyl)-1-(2,6-difluorobenzyl)-6-(4-nitrophenyl)-3-phenylthieno[2,3-d]pyrimidine-2,4(1H,3H)-dione 在 10 percent Pd/C/water 盐酸 、 甲酸 作用下， 以 乙醚 为溶剂， 反应 3.5h， 以87%的产率得到6-(4-aminophenyl)-5-(N-benzyl-N-methylaminomethyl)-1-(2,6-difluorobenzyl)-3-phenylthieno[2,3-d]pyrimidine-2,4(1H,3H)-dione
  参考文献：
  名称：

  发现在6-位带有对甲氧基脲基苯基部分的噻吩并[2,3-d]嘧啶-2,4-二酮：一种用于人类促黄体生成激素释放激素受体的高效且可口服生物利用的非肽拮抗剂。

  摘要：

  我们先前已经公开了第一种有效且口服有效的非肽类抗人黄体生成激素释放激素（LHRH）受体，即噻吩并[2,3-b]吡啶-4-酮衍生物T-98475（1）。已经通过采用用其他杂环代用品替代噻吩并吡啶-4-酮核的策略对开发非肽LHRH拮抗剂进行了广泛的研究。我们在本文中描述了一系列含有联芳基部分的噻吩并[2,3-d]嘧啶-2,4-二酮衍生物的设计和合成，这些衍生物导致发现了一种高效且口服活性的非肽LHRH拮抗剂， 5-（N-苄基-N-甲基氨基甲基）-1-（2,6-二氟苄基）-6- [4-（3-甲氧基脲基）苯基] -3-苯基噻吩并[2,3-d]嘧啶-2， 4（1H，3H）-二酮（9k：TAK-013）。化合物9k对人受体显示出高结合亲和力和有效的体外拮抗活性，其最大抑制浓度（IC（50））值分别为0.1和0.06 nM。口服9k能够以30 mg / kg的剂量在cast割的雄性食蟹猕猴中几乎完全抑制

  DOI：

  10.1021/jm020180i

文献信息

• Thienopyrimidine compounds, their production and use
  申请人：Takeda Chemical Industries, Ltd.

  公开号：US06297379B1

  公开（公告）日：2001-10-02

  A compound of formula (I) wherein R1 and R2 each is hydrogen, hydroxy, C1-4 alkoxy, C1-4 alkoxy-carbonyl or C1-4 alkyl which may be substituted; R3 is hydrogen, halogen, hydroxy or C1-4 alkoxy which may be substituted; or adjacent two R3 may form C1-4 alkylenedioxy; R4 is hydrogen or C1-4 alkyl; R6 is C1-4 alkyl which may be substituted or a group of the formula (A) wherein R5 is hydrogen of R4 and R5 may form heterocycle; and n is 0-5, or a salt thereof, has an excellent GnRH-antagonizing activity, and is useful for preventing or treating sex hormone-dependent diseases.

  式（I）的化合物，其中R1和R2分别是氢、羟基、C1-4烷氧基、C1-4烷氧羰基或C1-4烷基，可以被取代；R3是氢、卤素、羟基或C1-4烷氧基，可以被取代；或相邻的两个R3可以形成C1-4烷二氧基；R4是氢或C1-4烷基；R6是可以被取代的C1-4烷基或具有式（A）的基团，其中R5是R4的氢或R4和R5可以形成杂环；n为0-5，或其盐，具有出色的GnRH拮抗活性，并且用于预防或治疗性激素依赖性疾病。
• SUSTAINED RELEASE COMPOSITIONS
  申请人：Takeda Chemical Industries, Ltd.

  公开号：EP1291023A1

  公开（公告）日：2003-03-12

  A composition prepared by containing or blending a physiologically active non-peptide substance and a biodegradable polymer having two or more carboxylic groups at its end or a salt thereof features: (1) larger content of the physiologically active non-peptide substance can be contained, as well as release of the same can be controlled or accelerated, whereby secure pharmaceutical effect is achieved; (2) when the physiologically active non-peptide substance causes subcutaneous stimulation, an activity of canceling the stimulation by strongly acidic group at its end is expected; and (3) high glass transition point and high stability.

  通过含有或混合生理活性非肽物质和具有两个或两个以上羧基末端的可生物降解聚合物或其盐制备的组合物具有以下特点：（1）可以含有更多生理活性非肽物质，并且可以控制或加速其释放，从而实现安全的药效；（2）当生理活性非肽物质引起皮下刺激时，预计具有在其末端具有强酸性基团的活性来取消刺激；以及（3）高玻璃转变温度和高稳定性。
• Preventives/remedies for alzheimer's disease
  申请人：——

  公开号：US20030134863A1

  公开（公告）日：2003-07-17

  The present invention provides an agent for the prophylaxis or treatment of Alzheimer's disease. The agent for the prophylaxis or treatment of Alzheimer's disease of the present invention containing a compound having a GnRH antagonistic action shows low toxicity and has a superior preventive and therapeutic effect on Alzheimer's disease.

  本发明提供了一种用于预防或治疗阿尔茨海默病的药剂。本发明的用于预防或治疗阿尔茨海默病的药剂含有具有GnRH拮抗作用的化合物，显示出低毒性，并对阿尔茨海默病具有卓越的预防和治疗效果。
• MEDICINAL SOLUTIONS
  申请人：Takeda Chemical Industries, Ltd.

  公开号：EP1374855A1

  公开（公告）日：2004-01-02

  The present invention relates to a pharmaceutical solution containing a physiologically active non-peptide substance, an organic acid and a biocompatible organic solvent, and provides a pharmaceutical solution wherein a physiologically active non-peptide substance is dissolved at a high concentration.

  本发明涉及一种含有生理活性非肽物质、有机酸和生物相容性有机溶剂的药物溶液，并提供了一种药物溶液，其中生理活性非肽物质以高浓度溶解。
• Processes for the production of thienopyrimidine derivatives
  申请人：——

  公开号：US20030055269A1

  公开（公告）日：2003-03-20

  The present invention provides a process for producing an intermediate for thienopyrimidine derivatives having the GnRH antagonistic activity at an industrial large scale. The process for production of the present invention relates to a process for producing a compound represented by the formula (III): 1 wherein respective symbols have the same meanings as those described below, or a salt thereof, which comprises subjecting a compound represented by the formula (I): 2 wherein R 1 denotes hydrogen, nitro, halogen, phthalimido, mono- or di-(alkylcarbonyl)amino or alkoxy, or a salt thereof, to an acid halogenating reaction, which is successively reacted with malonic acid ester and magnesium alkoxide, treated with an acid, and reacted with sulfur and a compound represented by the formula: NCCH 2 COOR 2 [wherein R 2 denotes alkyl or aryl], or a salt thereof, in the presence of primary amine. According to the process of production of the present invention, thienopyrimidine derivatives having the GnRH antagonistic activity can be produced effectively and at an industrial large scale by a high yield and simple method.

  本发明提供了一种在工业大规模下生产具有GnRH拮抗活性的噻唑嘧啶衍生物中间体的方法。本发明的生产方法涉及生产以下化合物的方法（III）：其中各符号具有以下所述的相同含义，或其盐，包括将化合物（I）：其中R1表示氢，硝基，卤素，邻苯二甲酰亚胺，单个或二个（烷基羰基）氨基或烷氧基，或其盐，经过酸卤化反应，随后与丙二酸酯和镁烷氧化物反应，用酸处理，然后与硫和化合物（II）：NCCH2COOR2（其中R2表示烷基或芳基），或其盐，在原始胺的存在下反应。根据本发明的生产方法，通过高产率和简单的方法，可以有效地在工业大规模下生产具有GnRH拮抗活性的噻唑嘧啶衍生物。